EMEA-002377-PIP01-18

Key facts

Invented name
Empliciti
Active substance
Elotuzumab
Therapeutic area
Oncology
Decision number
P/0267/2018
PIP number
EMEA-002377-PIP01-18
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Multiple Myeloma
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

Tel. +44 1895 52 37 40
E-mail: medical.information@bms.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating